<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02358863</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0973</org_study_id>
    <nct_id>NCT02358863</nct_id>
  </id_info>
  <brief_title>Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach</brief_title>
  <acronym>mEGA</acronym>
  <official_title>A Pilot Study of Molecular Profile-Directed Chemotherapy for Metastatic HER2(-) Esophagogastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether molecular profile-directed therapy
      (otherwise known as personalized treatment) can improve the effectiveness of standard
      chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests
      will be performed on a sample of tumor; based on the results of these tests, a patient will
      be assigned to a chemotherapy treatment.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Issues with recruitment.
  </why_stopped>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 year</time_frame>
    <description>complete or partial response by RECIST criteria</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard chemotherapy doublet based on molecular testing using one of the following interventions:
Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified FOLFOX6</intervention_name>
    <description>Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>5-FU</other_name>
    <other_name>5-Flourouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel/Capecitabine</intervention_name>
    <description>Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin/Irinotecan</intervention_name>
    <description>Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Platinum</other_name>
    <other_name>CPT-11</other_name>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin/Docetaxel</intervention_name>
    <description>Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Platinum</other_name>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IRI/EPI</intervention_name>
    <description>Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Irinotecan</other_name>
    <other_name>CPT-11</other_name>
    <other_name>Epirubicin</other_name>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI/Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>Epirubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan/Docetaxel</intervention_name>
    <description>Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>CPT-11</other_name>
    <other_name>Camptosar</other_name>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 60-100 mg/m2 IV day 1 every 21 days</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced, measurable metastatic esophagogastric adenocarcinoma by RECIST criteria

          -  Patients who have had surgery or radiotherapy with or without neoadjuvant or adjuvant
             chemotherapy (the wash-out period will be at least 1 month)

          -  Patients who are not eligible for resection and are chemotherapy na√Øve

          -  Patients with HER2(-) status

          -  Patients who have tumor deposit(s) that are easily accessible by ultrasound or CT
             guidance

          -  Patients must have adequate organ function

          -  Patients must provide written informed consent

        Exclusion Criteria:

          -  Active concurrent malignancy, other than superficial, non-squamous cell carcinoma of
             the skin or uterine cervix, within the past three years

          -  ECOG performance status worse than 2

          -  Prior oral or intravenous chemotherapy for metastatic disease

          -  Patients with comorbidities that prevent them from being able to receive the
             chemotherapy regimen

          -  cardiac ejection fraction 45% or greater
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Marshall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2015</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 2, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

